{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T14:44:06Z","timestamp":1782744246077,"version":"3.54.5"},"reference-count":106,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Provincial Basic Research Special Fund","award":["BK20241837"],"award-info":[{"award-number":["BK20241837"]}]},{"DOI":"10.13039\/501100018557","name":"Science and Technology Project of Nantong City","doi-asserted-by":"publisher","award":["MS22022111"],"award-info":[{"award-number":["MS22022111"]}],"id":[{"id":"10.13039\/501100018557","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jiangsu Provincial Research Hospital Project","award":["YJXYY202204-XKB17"],"award-info":[{"award-number":["YJXYY202204-XKB17"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of malignant lymphoma in older adults. Treatment in this population remains challenging due to heightened genetic heterogeneity and reduced physiological reserve, which increase susceptibility to both treatment-related toxicity and the risk of undertreatment. Comprehensive geriatric assessment is essential to categorize patients as fit, unfit, or frail, enabling individualized therapeutic strategies. Fit patients benefit from standard R-CHOP or Pola-R-CHP regimens, while unfit patients are suitable for dose-reduced regimens. Anthracycline-containing therapy is recommended when feasible; alternatives such as etoposide or gemcitabine may be used when anthracyclines are contraindicated. Frail patients lack standardized treatment protocols, presenting a significant clinical dilemma; however, advances in geriatric assessment tools and novel therapies are expected to shift the management paradigms from purely palliative care to curative\u2011intent strategies. Current geriatric assessment tools have limitations, and the distinction between unfit and frail remains fluid. Dynamic fitness assessment and pre-phase treatment strategies may enable some patients to \u201cimprove\u201d to a higher fitness level. Emerging evidence supports the efficacy of novel targeted agents, including small-molecule inhibitors, bispecific antibodies, and antibody-drug conjugates, which are reshaping first-line treatment paradigms. Nevertheless, their implementation in community settings faces substantial practical barriers, such as the need for cytokine release syndrome monitoring, caregiver burden, financial toxicity, and adherence challenges. This review provides a comprehensive overview of current strategies and emerging directions for managing older adults with DLBCL.<\/jats:p>","DOI":"10.1177\/17588359261457855","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T03:07:53Z","timestamp":1782443273000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of diffuse large B\u2011cell lymphoma in older adults: current strategies and emerging directions"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7517-3665","authenticated-orcid":false,"given":"Jie","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China"},{"name":"Jiangsu Cooperative Lymphoma Group (JCLG), Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3381-1486","authenticated-orcid":false,"given":"Yaping","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China"},{"name":"Jiangsu Cooperative Lymphoma Group (JCLG), Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7565-7762","authenticated-orcid":false,"given":"Yongning","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China"},{"name":"Jiangsu Cooperative Lymphoma Group (JCLG), Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2371-3332","authenticated-orcid":false,"given":"Wenyu","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Nantong University, 20 Xisi Road, Nantong, Jiangsu 226001, China"},{"name":"Jiangsu Cooperative Lymphoma Group (JCLG), Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2023.11.004"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1975188"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21824"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP7YLTQPUSDQ5C"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2016.11.006"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-018-0555-8"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.686106"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.842439"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1365851"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100670"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1443332"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.20.00442"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(00)00089-5"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.953142"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24490"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.788176"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02465"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281407"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6856"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0260"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0361"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25107"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004777"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17554"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13641"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3551-y"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.21.00513"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2021.12.005"},{"key":"e_1_3_4_30_2","article-title":"TRAIL score: a simple model to predict immunochemotherapy tolerability in patients with diffuse large B-cell lymphoma","volume":"6","author":"Harris W","year":"2022","unstructured":"Harris W, Bataillard EJ, Choi Y, et al. TRAIL score: a simple model to predict immunochemotherapy tolerability in patients with diffuse large B-cell lymphoma. JCO Clin Cancer Inform 2022; 6: e2100121.","journal-title":"JCO Clin Cancer Inform"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.11.013"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12608"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-07164-w"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0738"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16049"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2023.265"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.131"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70122-0"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60313-X"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70002-0"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.4505"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30051-1"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115304"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014707"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.4582"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.930853"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.06.015"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-011-1814-6"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.11.003"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.600486"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004665"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1080\/10245332.2018.1509461"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.0990-18"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70069-9"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)30171-5"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12459"},{"key":"e_1_3_4_58_2","first-page":"2455","article-title":"Analysis of the effect of R-CHOP regimen of pegylated liposomal doxorubicin on elderly patients with stage III-IV diffuse large B-cell lymphoma","volume":"34","author":"Zhou X","year":"2021","unstructured":"Zhou X, Wang Y, Li X. Analysis of the effect of R-CHOP regimen of pegylated liposomal doxorubicin on elderly patients with stage III-IV diffuse large B-cell lymphoma. Pak J Pharm Sci 2021; 34(6(Special)): 2455\u20132459.","journal-title":"Pak J Pharm Sci"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp544"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.572321"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023009839"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70099"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.7586"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30054-1"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002982"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1096356"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000808"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11237162"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967820.91359.ec"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06412-z"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-140384"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206913"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01725"},{"key":"e_1_3_4_74_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157768"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-188854"},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199271"},{"key":"e_1_3_4_77_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199652"},{"key":"e_1_3_4_78_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02403"},{"key":"e_1_3_4_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70191-3"},{"key":"e_1_3_4_80_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01366"},{"key":"e_1_3_4_81_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02666"},{"key":"e_1_3_4_82_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00033"},{"key":"e_1_3_4_83_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-020-00948-9"},{"key":"e_1_3_4_84_2","doi-asserted-by":"publisher","DOI":"10.1177\/20406207241292446"},{"key":"e_1_3_4_85_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022019173"},{"key":"e_1_3_4_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-7568(22)00123-4"},{"key":"e_1_3_4_87_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-022-00314-w"},{"issue":"1","key":"e_1_3_4_88_2","first-page":"605","article-title":"The efficacy and safety of ZR2 versus R-CHOP-like for elderly patients with newly diagnosed diffuse large B cell lymphoma: a single-center prospective study in China","volume":"104","author":"Jiang P","year":"2025","unstructured":"Jiang P, Li R, Li H, et al. The efficacy and safety of ZR2 versus R-CHOP-like for elderly patients with newly diagnosed diffuse large B cell lymphoma: a single-center prospective study in China. Ann Hematol 2025; 104(1): 605\u2013615.","journal-title":"Ann Hematol"},{"key":"e_1_3_4_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103157"},{"key":"e_1_3_4_90_2","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.29"},{"key":"e_1_3_4_91_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006578"},{"key":"e_1_3_4_92_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.3402"},{"key":"e_1_3_4_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30120-4"},{"key":"e_1_3_4_94_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-14295-6"},{"key":"e_1_3_4_95_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2007.06.009"},{"key":"e_1_3_4_96_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2021.10.003"},{"key":"e_1_3_4_97_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3741"},{"issue":"3","key":"e_1_3_4_98_2","first-page":"457","article-title":"Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma","volume":"2","author":"Knox SJ","year":"1996","unstructured":"Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996; 2(3): 457\u2013470.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_4_99_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70093_160"},{"key":"e_1_3_4_100_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02410-8"},{"key":"e_1_3_4_101_2","doi-asserted-by":"publisher","DOI":"10.1177\/10600280211022281"},{"key":"e_1_3_4_102_2","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30120738"},{"key":"e_1_3_4_103_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.720704"},{"key":"e_1_3_4_104_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.7031"},{"key":"e_1_3_4_105_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00843-5"},{"key":"e_1_3_4_106_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30935-5"},{"key":"e_1_3_4_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.09.004"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261457855","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359261457855","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261457855","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:47:03Z","timestamp":1782740823000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359261457855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":106,"alternative-id":["10.1177\/17588359261457855"],"URL":"https:\/\/doi.org\/10.1177\/17588359261457855","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"17588359261457855"}}